OncoGenex Pharmaceuticals, Inc. today announced that it has priced an underwritten public offering of 4,165,000 shares of its common stock at a purchase price of $12.00 per share.

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients with advanced bladder cancer. The trial is designed to assess the potential survival benefit of combining OGX-427 with ...

OncoGenex Pharmaceuticals, Inc. announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients with advanced bladder cancer.

OncoGenex Pharmaceuticals, Inc. today provided an update on current events and activities and announced its second quarter financial results.

Teva Pharmaceutical Industries Ltd.(NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that new preclinical data of their investigational compound custirsen (OGX-011/TV-1011) in castrate resistant prostate cancer (CRPC) were presented this week at the 102nd Annual Meeting of the AACR. These data provide additional evidence in support of the clinical ...

OncoGenex Pharmaceuticals, Inc. announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011.

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced yesterday (4th April) that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011. The study demonstrated the ability of OGX-427 to inhibit Heat Shock Protein 27 (Hsp27), a cell-survival protein believed to play an important role in ...

OncoGenex Pharmaceuticals, Inc. today announced that it has completed a public offering of 3,174,602 units at a price to the public of $15.75 per unit for an aggregate offering amount of $50 million, as previously announced on October 18, 2010.

OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering

OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering

OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering

BOTHELL, WA and VANCOUVER, Oct. 4 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that management of OncoGenex will present at the 9th Annual BIO Investor Forum on Wednesday, October 6 at 10:30 a.m. PDT at The Palace Hotel in San Francisco, CA. Live webcasts ...